Literature DB >> 33879868

Copanlisib safe and active in combination.

David Killock1.   

Abstract

Entities:  

Year:  2021        PMID： 33879868     DOI： 10.1038/s41571-021-00512-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Matthew J Matasar; Marcelo Capra; Muhit Özcan; Fangfang Lv; Wei Li; Eduardo Yañez; Katya Sapunarova; Tongyu Lin; Jie Jin; Wojciech Jurczak; Aryan Hamed; Ming-Chung Wang; Ross Baker; Igor Bondarenko; Qingyuan Zhang; Jifeng Feng; Klaus Geissler; Mihaela Lazaroiu; Guray Saydam; Árpád Szomor; Krimo Bouabdallah; Rinat Galiulin; Toshiki Uchida; Lidia Mongay Soler; Anjun Cao; Florian Hiemeyer; Aruna Mehra; Barrett H Childs; Yuankai Shi; Pier Luigi Zinzani
Journal:  Lancet Oncol       Date:  2021-04-10       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.